Somagenics, Inc.

Santa Cruz, CA · Medtech · Private

HASL-free-Seq, a proprietary method and kit for preparing cell-free DNA libraries for next-generation sequencing that captures ultrashort circulating tumor DNA fragments for liquid biopsy cancer diagn

Claim this profile

Follows are private to you and power your alerts

Updated · somagenics.com

Sector
Medtech
Headquarters
Santa Cruz, CA
Total capital
$13.1M
Federal grants
$13.1M
18 awards · 2015–2021
Rank in peer group#11 of 112
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
None on recordNo federal contract awards found.
Granted patents
9
21 pending · first 2016
Rank in peer group#6 of 112

Capital timeline

2015201620172018201920202021FEDERAL ↑EQUITY ↓Cumulative $13.1M$990K$804K$2.9M$1M$965K$1.6M
2015201720192021FEDERAL ↑EQUITY ↓Cumulative $13.1M$990K$2.9M$1M$1.6M

Latest events

  • Federal grantHealth and Human S · Phase II · Advanced method for preparing cell-free DNA sequencing libraries$786K
  • Federal grantHealth and Human S · Phase II · Advanced method for preparing cell-free DNA sequencing libraries$1.6M
  • Federal grantHealth and Human S · Phase II · Therapeutic Development of RNAi-based inhibitors against the Hepatitis Delta Virus$965K
  • Federal grantHealth and Human S · Phase II · Highly accurate small-RNA sequencing of single cells (RealSeq-SC)$1
  • Federal grantHealth and Human S · Phase I · A novel sshRNA-antimiR combination therapy for accelerating healing of diabetic foot ulcers$300K
  • Federal grantHealth and Human S · Phase II · Therapeutic Development of RNAi-based inhibitors against the Hepatitis Delta Virus$1M
  • Federal grantHealth and Human S · Phase II · miR-SEQ: Highly efficient targeted quantification of extracellular miRNAs by Next Generation Sequencing$292K
Show 11 earlier federal awards
  • Federal grantHealth and Human S · Phase II · Administrative supplement (instrumentation) to: miR-SEQ: Highly efficient targeted quantification of extracellular miRNAs by Next Generation Sequencing$288K
  • Federal grantHealth and Human S · Phase II · Therapeutic Development of RNAi-based inhibitors against the Hepatitis Delta Virus$2.9M
  • Federal grantHealth and Human S · Phase II · miR-SEQ: Highly efficient targeted quantification of extracellular miRNAs by Next Generation Sequencing$623K
  • Federal grantHealth and Human S · Phase II · A method for preparing unbiased miRNA sequencing libraries (miR-ACS)$804K
  • Federal grantHealth and Human S · Phase I · Highly accurate small-RNA sequencing of single cells (RealSeq-SC)$281K
  • Federal grantHealth and Human S · Phase I · Advanced method for preparing cell-free DNA sequencing libraries$270K
  • Federal grantHealth and Human S · Phase II · A method for preparing unbiased miRNA sequencing libraries (miR-ACS)$990K
  • Federal grantHealth and Human S · Phase I · miR-SEQ: Highly efficient targeted quantification of extracellular miRNAs by Next Generation Sequencing$350K
  • Federal grantHealth and Human S · Phase I · An improved RT-qPCR method for quantitation of fragmented mRNAs$288K
  • Federal grantHealth and Human S · Phase II · Accelerating Wound Healing through RNAi$683K
  • Federal grantHealth and Human S · Phase I · miR-SEQ: Highly efficient targeted quantification of extracellular miRNAs by Next Generation Sequencing$700K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 112 peers

Line = median

Medtech · Instrument

  • Federal grants#11 · top 10%
  • Granted patents#6 · top 5%
  • Linked publications#13 · top 12%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 9 granted of 30
Show all 30 patent records

Recent research by its founders

  • A method of comprehensive sequencing analysis of the small RNA fragmentome (RiboMarker)20260 cites
  • Transcriptomic characterization of <i>Coccidioides</i> morphological states using RiboMarker-enhanced RNA sequencing20260 cites
  • A method of comprehensive sequencing analysis of the small RNA fragmentome (RiboMarker <sup>®</sup> )20250 cites

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .